Doximity (DOCS) shares plummeted 23.3% to a record low following a disappointing full-year revenue outlook. Management projects annual revenue between $664 million and $676 million, missing Wall Street’s $687 million estimate. While top pharma clients are shifting up to 20% of their budgets toward AI, rising compute costs are compressing margins for the medical networking platform. Despite the sell-off, Doximity is betting on long-term AI adoption to drive the next phase of healthcare digital transformation.
|
China’s President Xi Jinping has told Do...
'The Big Money Show' panel discusses the...
‘The Big Money Show’ panelists discuss A...
Doximity (DOCS) shares plummeted 23.3% t...
FOX Business' Stuart Varney and Lauren S...
Rep. John Moolenaar, R-Mich., joins 'Var...
On this week's episode of The Deal, Alex...
Hockey rinks are notoriously difficult b...
‘The Big Money Show’ breaks down Preside...
Sen. Steve Daines, R-Mont., discusses th...
As usual, Google delivered much of its c...